【摘要】：正近日,美國心臟病學(xué)會、美國心臟協(xié)會和美國心力衰竭協(xié)會聯(lián)合對2013年心力衰竭指南進(jìn)行了更新,主要內(nèi)容為心力衰竭相關(guān)生物標(biāo)志物、射血分?jǐn)?shù)保留性心力衰竭(HFpEF)治療、重要合并癥處理,要點(diǎn)總結(jié)如下:1生物標(biāo)志物推薦可能發(fā)生心力衰竭的患者應(yīng)用腦鈉肽(BNP)進(jìn)行篩查(Ⅱa,B-R),然后接受專業(yè)團(tuán)隊(duì)治療,優(yōu)化指南推薦的藥物治療(GDMT),預(yù)
[Abstract]:Recently, the American Heart Association, the American Heart Association and the American Heart failure Association jointly updated the 2013 Heart failure guidelines, which focus on biomarkers related to heart failure. In the treatment of (HFpEF) with ejection fraction reserved heart failure, the main points are summarized as follows: (1) the biomarkers recommend the use of brain natriuretic peptide (BNP) (BNP) to screen patients with heart failure (鈪，

本文編號：2358172